Cerovene

Founded in 2016 and based in Boston, USA, Cerovene operates as a private, revenue-generating service and product development company in the biotech space. It leverages a suite of proprietary modified-release drug delivery technologies, such as its patented coated capsule system, to create new dosage forms for existing chemical entities, aiming to improve patient compliance and extend product lifecycles. The company's business model combines service-based contract development and manufacturing (CDMO) with internal product development to create later-stage pipeline opportunities for ANDA or NDA approvals. Its primary focus is within neuroscience, offering partners novel formulation solutions for life cycle management.

Proprietary drug delivery technologies for modified release, including patented coated capsule technology that coats the capsule shell with API to create new dosage forms for life cycle management.

Cerovene competes with a broad range of CDMOs offering formulation development and with specialized drug delivery technology companies. Its differentiation lies in its specific focus on life cycle management and its patented coated capsule technology, but it faces competition from larger, more established players with greater resources and broader service portfolios.